Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Bonafede

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
The Journal of Laboratory and Clinical Medicine|January 9, 1998
Emerging antibiotic resistanceM Bonafede, L B Rice
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Indirect Costs Among Patients with Hepatitis C VirusL A Palmer, M M Bonafede
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Trends In Prescription Opiate Use Among Patients With Commercial Or Government Sponsored Health Insurance In the Us From 2010-2013M M Bonafede, L A Palmer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Risk of Relapse Among Propensity Score Matched Multiple Sclerosis Patients Receiving Natalizumab or Platform Therapy in the USC Watson, M M Bonafede, B H Johnson
CNS Drugs|June 27, 2015
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US PatientsBarbara H Johnson, Machaon M Bonafede, Crystal Watson
American Health & Drug Benefits|July 4, 2014
Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured PopulationSaurabh Ray, Machaon M Bonafede, Nimish A Mohile
Clinicoeconomics and Outcomes Research : CEOR|January 1, 2014
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the USMachaon M Bonafede, Barbara H Johnson, Crystal Watson
Clinicoeconomics and Outcomes Research : CEOR|March 12, 2016
Short- and longer-term health-care resource utilization and costs associated with acute ischemic strokeBarbara H Johnson, Machaon M Bonafede, Crystal Watson
Clinical Therapeutics|October 22, 2013
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United StatesMachaon M Bonafede, Barbara H Johnson, Madé Wenten, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 20, 2015
Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemiaMachaon M Bonafede, Barbara H Johnson, Akshara Richhariya, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
The Journal of Laboratory and Clinical Medicine|January 9, 1998
Emerging antibiotic resistanceM Bonafede, L B Rice
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Indirect Costs Among Patients with Hepatitis C VirusL A Palmer, M M Bonafede
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Trends In Prescription Opiate Use Among Patients With Commercial Or Government Sponsored Health Insurance In the Us From 2010-2013M M Bonafede, L A Palmer
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 21, 2016
Risk of Relapse Among Propensity Score Matched Multiple Sclerosis Patients Receiving Natalizumab or Platform Therapy in the USC Watson, M M Bonafede, B H Johnson
CNS Drugs|June 27, 2015
Platform Therapy Compared with Natalizumab for Multiple Sclerosis: Relapse Rates and Time to Relapse Among Propensity Score-Matched US PatientsBarbara H Johnson, Machaon M Bonafede, Crystal Watson
American Health & Drug Benefits|July 4, 2014
Treatment Patterns, Survival, and Healthcare Costs of Patients with Malignant Gliomas in a Large US Commercially Insured PopulationSaurabh Ray, Machaon M Bonafede, Nimish A Mohile
Clinicoeconomics and Outcomes Research : CEOR|January 1, 2014
Health care-resource utilization before and after natalizumab initiation in multiple sclerosis patients in the USMachaon M Bonafede, Barbara H Johnson, Crystal Watson
Clinicoeconomics and Outcomes Research : CEOR|March 12, 2016
Short- and longer-term health-care resource utilization and costs associated with acute ischemic strokeBarbara H Johnson, Machaon M Bonafede, Crystal Watson
Clinical Therapeutics|October 22, 2013
Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United StatesMachaon M Bonafede, Barbara H Johnson, Madé Wenten, et al.
Clinicoeconomics and Outcomes Research : CEOR|June 20, 2015
Medical costs associated with cardiovascular events among high-risk patients with hyperlipidemiaMachaon M Bonafede, Barbara H Johnson, Akshara Richhariya, et al.
Pageof 5